Three years on, nearly half of the women with 'no options left' ovarian cancer are still here

When ovarian cancer comes back after chemotherapy, doctors often have little left to offer — the women in this study had already been through a median of four rounds of treatment. A new two-medicine combination, presented this week at the 2026 International Gynecologic Cancer Society meeting in Montréal, helps the body's own immune system find and fight the cancer cells instead of poisoning them directly. Three years after treatment, an estimated 48% of the 35 women evaluated were still alive — the same figure as at two years, suggesting the benefit lasts. One in four of all treated patients (11 of 44) were alive and off every therapy. The treatment is still experimental, but for a cancer with few second chances, 'durable' is the word that matters.